REFERENCES

1. Durga YK, Pusapati RV. Drug resistance in glioblastoma: challenges, mechanisms and therapeutic strategies (Review). Mol Clin Oncol. 2026;24:4.

2. Smerdi D, Moutafi M, Kotsantis I, Stavrinou LC, Psyrri A. Overcoming resistance to temozolomide in glioblastoma: a scoping review of preclinical and clinical data. Life. 2024;14:673.

3. Wu H, Gao W, Chen P, Wei Y, Zhao H, Wang F. Research progress of drug resistance mechanism of temozolomide in the treatment of glioblastoma. Heliyon. 2024;10:e39984.

4. Bouzinab K, Summers H, Zhang J, et al. In search of effective therapies to overcome resistance to temozolomide in brain tumours. Cancer Drug Resist. 2019;2:1018-31.

5. Lin F, de Gooijer MC, Hanekamp D, Brandsma D, Beijnen JH, van Tellingen O. Targeting core (mutated) pathways of high-grade gliomas: challenges of intrinsic resistance and drug efflux. CNS Oncol. 2013;2:271-88.

6. Cruz JVR, Batista C, Afonso BH, et al. Obstacles to glioblastoma treatment two decades after temozolomide. Cancers. 2022;14:3203.

7. Ortiz R, Perazzoli G, Cabeza L, et al. Temozolomide: an updated overview of resistance mechanisms, nanotechnology advances and clinical applications. Curr Neuropharmacol. 2021;19:513-37.

8. Harder BG, Blomquist MR, Wang J, et al. Developments in blood-brain barrier penetrance and drug repurposing for improved treatment of glioblastoma. Front Oncol. 2018;8:462.

9. Hanna C, Kurian KM, Williams K, et al. Pharmacokinetics, safety, and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial. Neuro Oncol. 2020;22:1840-50.

10. Ostermann S, Csajka C, Buclin T, et al. Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin Cancer Res. 2004;10:3728-36.

11. Portnow J, Badie B, Chen M, Liu A, Blanchard S, Synold TW. The neuropharmacokinetics of temozolomide in patients with resectable brain tumors: potential implications for the current approach to chemoradiation. Clin Cancer Res. 2009;15:7092-8.

12. Jackson S, Weingart J, Nduom EK, et al. The effect of an adenosine A2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma. Fluids Barriers CNS. 2018;15:2.

13. Büsker S, Jäger W, Poschner S, et al. Pharmacokinetics of metronomic temozolomide in cerebrospinal fluid of children with malignant central nervous system tumors. Cancer Chemother Pharmacol. 2022;89:617-27.

14. Mainprize T, Lipsman N, Huang Y, et al. Blood-brain barrier opening in primary brain tumors with non-invasive MR-guided focused ultrasound: a clinical safety and feasibility study. Sci Rep. 2019;9:321.

15. Park SH, Kim MJ, Jung HH, et al. One-year outcome of multiple blood-brain barrier disruptions with temozolomide for the treatment of glioblastoma. Front Oncol. 2020;10:1663.

16. Woodworth GF, Anastasiadis P, Ozair A, et al. Microbubble-enhanced transcranial focused ultrasound with temozolomide for patients with high-grade glioma (BT008NA): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 2025;26:1651-64.

17. Talele S, Zhang W, Burgenske DM, et al. Brain distribution of berzosertib: an ataxia telangiectasia and Rad3-related protein inhibitor for the treatment of glioblastoma. J Pharmacol Exp Ther. 2021;379:343-57.

18. Rathi S, Mladek AC, Oh JH, et al. Factors influencing the central nervous system (CNS) distribution of the ataxia telangiectasia mutated and Rad3-related inhibitor elimusertib (BAY1895344): implications for the treatment of CNS tumors. J Pharmacol Exp Ther. 2024;391:346-60.

19. Liu Y, Wang W, Zhang D, et al. Brain co-delivery of first-line chemotherapy drug and epigenetic bromodomain inhibitor for multidimensional enhanced synergistic glioblastoma therapy. Exploration. 2022;2:20210274.

20. Dhungel L, Rowsey ME, Harris C, Raucher D. Synergistic effects of temozolomide and doxorubicin in the treatment of glioblastoma multiforme: enhancing efficacy through combination therapy. Molecules. 2024;29:840.

21. Da Ros M, Iorio AL, De Gregorio V, et al. Aldoxorubicin and temozolomide combination in a xenograft mice model of human glioblastoma. Oncotarget. 2018;9:34935-44.

22. Ribeiro Morais G, Nwokolo GC, Lamptey Mills HNL, Wheelhouse RT, Falconer RA. Exploiting methyl triazenes as attractive alternatives to temozolomide and dacarbazine for cancer therapy. Molecules. 2026;31:1103.

23. de Gooijer MC, de Vries NA, Buckle T, et al. Improved brain penetration and antitumor efficacy of temozolomide by inhibition of ABCB1 and ABCG2. Neoplasia. 2018;20:710-20.

24. Amarandi RM, Ibanescu A, Carasevici E, Marin L, Dragoi B. Liposomal-based formulations: a path from basic research to temozolomide delivery inside glioblastoma tissue. Pharmaceutics. 2022;14:308.

25. Ke G, Zhang M, Hu P, et al. Exploratory study on nanoparticle co-delivery of temozolomide and ligustilide for enhanced brain tumor therapy. Pharmaceutics. 2025;17:191.

26. Thomas RG, Kim S, Tran TA, et al. Magnet-guided temozolomide and ferucarbotran loaded nanoparticles to enhance therapeutic efficacy in glioma model. Nanomaterials. 2024;14:939.

27. Deligne C, Hachani J, Duban-Deweer S, et al. Development of a human in vitro blood-brain tumor barrier model of diffuse intrinsic pontine glioma to better understand the chemoresistance. Fluids Barriers CNS. 2020;17:37.

28. Ferber S, Tiram G, Sousa-Herves A, et al. Co-targeting the tumor endothelium and P-selectin-expressing glioblastoma cells leads to a remarkable therapeutic outcome. Elife. 2017;6:e25281.

29. Vézina A, Manglani M, Morris D, et al. Adenosine A2A receptor activation enhances blood-tumor barrier permeability in a rodent glioma model. Mol Cancer Res. 2021;19:2081-95.

30. Perazzoli G, Prados J, Ortiz R, et al. Temozolomide resistance in glioblastoma cell lines: implication of MGMT, MMR, P-glycoprotein and CD133 expression. PLoS One. 2015;10:e0140131.

31. Riganti C, Salaroglio IC, Pinzòn-Daza ML, et al. Temozolomide down-regulates P-glycoprotein in human blood-brain barrier cells by disrupting Wnt3 signaling. Cell Mol Life Sci. 2014;71:499-516.

32. Riganti C, Salaroglio IC, Caldera V, et al. Temozolomide downregulates P-glycoprotein expression in glioblastoma stem cells by interfering with the Wnt3a/glycogen synthase-3 kinase/β-catenin pathway. Neuro Oncol. 2013;15:1502-17.

33. Tivnan A, Zakaria Z, O’Leary C, et al. Inhibition of multidrug resistance protein 1 (MRP1) improves chemotherapy drug response in primary and recurrent glioblastoma multiforme. Front Neurosci. 2015;9:218.

34. de Souza I, Monteiro LKS, Guedes CB, et al. High levels of NRF2 sensitize temozolomide-resistant glioblastoma cells to ferroptosis via ABCC1/MRP1 upregulation. Cell Death Dis. 2022;13:591.

35. Lee CAA, Banerjee P, Wilson BJ, et al. Targeting the ABC transporter ABCB5 sensitizes glioblastoma to temozolomide-induced apoptosis through a cell-cycle checkpoint regulation mechanism. J Biol Chem. 2020;295:7774-88.

36. Wang SM, Lin WC, Lin HY, Chen YL, Ko CY, Wang JM. CCAAT/Enhancer-binding protein delta mediates glioma stem-like cell enrichment and ATP-binding cassette transporter ABCA1 activation for temozolomide resistance in glioblastoma. Cell Death Discov. 2021;7:8.

37. Yan Y, Liu Y, Liang Q, Xu Z. Drug metabolism-related gene ABCA1 augments temozolomide chemoresistance and immune infiltration abundance of M2 macrophages in glioma. Eur J Med Res. 2023;28:373.

38. Diao H, Sun Y, Zhou X, et al. GLUT3 enhances chemosensitivity in glioblastoma by transporting temozolomide and capecitabine. Cell Death Discov. 2025;11:382.

39. Bahrami K, Kärkkäinen J, Bibi S, et al. Specific transport of temozolomide does not override DNA repair-mediated chemoresistance. Eur J Pharm Sci. 2024;195:106661.

40. Xu Y, Yang X, Mei S, Sun Y, Li J. Acquisition of temozolomide resistance by the rat C6 glioma cell line increases cell migration and side population phenotype. Oncol Rep. 2019;42:2355-62.

41. Banelli B, Carra E, Barbieri F, et al. The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma. Cell Cycle. 2015;14:3418-29.

42. Brandt B, Németh M, Berta G, et al. A promising way to overcome temozolomide resistance through inhibition of protein neddylation in glioblastoma cell lines. Int J Mol Sci. 2023;24:7929.

43. Mujumdar P, Kopecka J, Bua S, Supuran CT, Riganti C, Poulsen SA. Carbonic anhydrase XII inhibitors overcome temozolomide resistance in glioblastoma. J Med Chem. 2019;62:4174-92.

44. Zou Y, Liu Z, Zhou Y, et al. TRPC5 mediates TMZ resistance in TMZ-resistant glioblastoma cells via NFATc3-P-gp pathway. Transl Oncol. 2021;14:101214.

45. Zhang X, Liu X, Zhou W, et al. Fasudil increases temozolomide sensitivity and suppresses temozolomide-resistant glioma growth via inhibiting ROCK2/ABCG2. Cell Death Dis. 2018;9:190.

46. Silva JA, Colquhoun A. Effect of polyunsaturated fatty acids on temozolomide drug-sensitive and drug-resistant glioblastoma cells. Biomedicines. 2023;11:779.

47. Qiu R, Zhang J, Ge C, et al. Ginsenosides Rg1 and CK control temozolomide resistance in glioblastoma cells by modulating cholesterol efflux and lipid raft distribution. Evid Based Complement Alternat Med. 2022;2022:1897508.

48. Pessina S, Cantini G, Kapetis D, et al. The multidrug-resistance transporter Abcc3 protects NK cells from chemotherapy in a murine model of malignant glioma. Oncoimmunology. 2016;5:e1108513.

49. Ha W, Sevim-Nalkiran H, Zaman AM, et al. Ibudilast sensitizes glioblastoma to temozolomide by targeting macrophage migration inhibitory factor (MIF). Sci Rep. 2019;9:2905.

50. Kim SS, Harford JB, Moghe M, Rait A, Pirollo KF, Chang EH. Targeted nanocomplex carrying siRNA against MALAT1 sensitizes glioblastoma to temozolomide. Nucleic Acids Res. 2018;46:1424-40.

51. Che J, DePalma TJ, Sivakumar H, et al. αCT1 peptide sensitizes glioma cells to temozolomide in a glioblastoma organoid platform. Biotechnol Bioeng. 2023;120:1108-19.

52. Tso JL, Yang S, Menjivar JC, et al. Bone morphogenetic protein 7 sensitizes O6-methylguanine methyltransferase expressing-glioblastoma stem cells to clinically relevant dose of temozolomide. Mol Cancer. 2015;14:189.

53. Minea RO, Duc TC, Swenson SD, et al. Developing a clinically relevant radiosensitizer for temozolomide-resistant gliomas. PLoS One. 2020;15:e0238238.

54. Harder BG, Peng S, Sereduk CP, et al. Inhibition of phosphatidylinositol 3-kinase by PX-866 suppresses temozolomide-induced autophagy and promotes apoptosis in glioblastoma cells. Mol Med. 2019;25:49.

55. Buccarelli M, Marconi M, Pacioni S, et al. Inhibition of autophagy increases susceptibility of glioblastoma stem cells to temozolomide by igniting ferroptosis. Cell Death Dis. 2018;9:841.

56. Zhao Z, Liu M, Long W, et al. Knockdown lncRNA CRNDE enhances temozolomide chemosensitivity by regulating autophagy in glioblastoma. Cancer Cell Int. 2021;21:456.

57. Karło W, Długoń M, Gutowska I, Wszołek A, Żwierełło W. Targeting ferroptosis in glioblastoma: molecular mechanisms, tumor microenvironment, and therapeutic opportunities. Cancers. 2026;18:2018.

58. Zhao J, Cui X, Zhan Q, et al. CRISPR-Cas9 library screening combined with an exosome-targeted delivery system addresses tumorigenesis/TMZ resistance in the mesenchymal subtype of glioblastoma. Theranostics. 2024;14:2835-55.

59. Xing H, Chen Y, Li H, Wang M, Cao Y, Liu X. ARL13B is regulated by the ERK/P90 pathway and mediates TMZ resistance in glioblastoma via microvesicles. Sci Rep. 2026;16:28405.

60. Hong B, Yang E, Su D, et al. EPIC-1042 as a potent PTRF/Cavin1-caveolin-1 interaction inhibitor to induce PARP1 autophagic degradation and suppress temozolomide efflux for glioblastoma. Neuro Oncol. 2024;26:100-14.

61. Araujo-Abad S, Manresa-Manresa A, Rodríguez-Cañas E, et al. Glioblastoma-derived small extracellular vesicles: nanoparticles for glioma treatment. Int J Mol Sci. 2023;24:5910.

62. Yekula A, Taylor A, Beecroft A, et al. The role of extracellular vesicles in acquisition of resistance to therapy in glioblastomas. Cancer Drug Resist. 2021;4:1-16.

63. Kosgodage US, Uysal-Onganer P, MacLatchy A, et al. Cannabidiol affects extracellular vesicle release, miR21 and miR126, and reduces prohibitin protein in glioblastoma multiforme cells. Transl Oncol. 2019;12:513-22.

64. Pourmasoumi P, Abdouss M, Farhadi M, Jameie SB, Khonakdar HA. Co-delivery of temozolomide and quercetin with folic acid-conjugated exosomes in glioblastoma treatment. Nanomedicine. 2024;19:2271-87.

65. Liu X, Cao Z, Liu N, et al. Kill two birds with one stone: engineered exosome-mediated delivery of cholesterol modified YY1-siRNA enhances chemoradiotherapy sensitivity of glioblastoma. Front Pharmacol. 2022;13:975291.

66. Wang S, Yu Y, Wang A, et al. Temozolomide hexadecyl ester targeted plga nanoparticles for drug-resistant glioblastoma therapy via intranasal administration. Front Pharmacol. 2022;13:965789.

67. Rehman FU, Rauf MA, Ullah S, et al. Ultrasound-activated nano-TiO2 loaded with temozolomide paves the way for resection of chemoresistant glioblastoma multiforme. Cancer Nano. 2021;12:17.

68. Lam FC, Morton SW, Wyckoff J, et al. Enhanced efficacy of combined temozolomide and bromodomain inhibitor therapy for gliomas using targeted nanoparticles. Nat Commun. 2018;9:1991.

69. Aytekin E, Maksoud S, Tannous BA, Pehlivan SB, Badr CE. Dual-action nanotherapy: temozolomide-loaded, anti-PD-L1 scFv-functionalized lipid nanocarriers for targeted glioblastoma therapy. Eur J Pharm Sci. 2025;213:107255.

70. Song Z, Huang X, Wang J, Cai F, Zhao P, Yan F. Targeted delivery of liposomal temozolomide enhanced anti-glioblastoma efficacy through ultrasound-mediated blood-brain barrier opening. Pharmaceutics. 2021;13:1270.

71. Wang Z, Liu Y, Xiao Y, et al. Intelligent nanoparticles with pH-sensitive co-delivery of temozolomide and siEGFR to ameliorate glioma therapy. Front Genet. 2022;13:921051.

72. Haseeb M, Khan I, Kartal Z, Mahfooz S, Hatiboglu MA. Status quo in the liposome-based therapeutic strategies against glioblastoma: “targeting the tumor and tumor microenvironment”. Int J Mol Sci. 2024;25:11271.

73. Zarneshan SN, Aghaz F. Engineered nanoparticles as a promising drug delivery system for glioblastoma multiforme treatment. Ther Deliv. 2025;16:593-606.

74. Mishra P, Gupta P, Markowska A, Ghavami S, Markowski J, Łos MJ. Advancements in drug delivery systems in glioblastoma therapy. Int J Mol Sci. 2026;27:2298.

75. Sousa DM, Loureiro JA, Pereira MC, Ramalho MJ. Surface-modified polymeric nanoparticles for glioblastoma therapy: a review on targeting strategies and delivery of repurposed drugs and off-label non-alkylating agents. Pharmaceutics. 2026;18:435.

76. Hegde MM, Palkar P, Mutalik SP, Mutalik S, Goda JS, Rao BSS. Enhancing glioblastoma cytotoxicity through encapsulating O6-benzylguanine and temozolomide in PEGylated liposomal nanocarrier: an in vitro study. 3 Biotech. 2024;14:275.

77. Kim SS, Rait A, Kim E, et al. A nanoparticle carrying the p53 gene targets tumors including cancer stem cells, sensitizes glioblastoma to chemotherapy and improves survival. ACS Nano. 2014;8:5494-514.

78. Angom RS, Rachamala HK, Nakka NMR, et al. Surface-engineered dual drug-loaded tumor-targeted liposomal nanoparticles to overcome the therapeutic resistance in glioblastoma multiforme. Commun Med. 2026;6:152.

79. Wang H, Li L, Ye J, et al. Improved safety and anti-glioblastoma efficacy of CAT3-encapsulated SMEDDS through metabolism modification. Molecules. 2021;26:484.

80. Bayanati M, Khosroshahi AG, Alvandi M, Mahboobian MM, Sun F. Fabrication of a thermosensitive in situ gel nanoemulsion for nose to brain delivery of temozolomide. J Nanomater. 2021.

81. Morales DE, Mousa S. Intranasal delivery in glioblastoma treatment: prospective molecular treatment modalities. Heliyon. 2022;8:e09517.

82. Yang Q, Zhou Y, Chen J, Huang N, Wang Z, Cheng Y. Gene therapy for drug-resistant glioblastoma via lipid-polymer hybrid nanoparticles combined with focused ultrasound. Int J Nanomedicine. 2021;16:185-99.

83. Bauer JA, Sysel AM, Dunphy MJ. Selective blood-brain barrier penetration and tumor targeting of nitrosylcobalamin in glioblastoma: pharmacokinetics, tissue distribution, and synergistic activity with trail and temozolomide. Oncoscience. 2026;13:120-9.

84. Zhang X, Chen Y, Yao J, et al. β-elemene combined with temozolomide in treatment of brain glioma. Biochem Biophys Rep. 2021;28:101144.

85. Persano F, Gigli G, Leporatti S. Natural compounds as promising adjuvant agents in the treatment of gliomas. Int J Mol Sci. 2022;23:3360.

86. Alfonso-Triguero P, Lorenzo J, Candiota AP, Arús C, Ruiz-Molina D, Novio F. Platinum-based nanoformulations for glioblastoma treatment: the resurgence of platinum drugs? Nanomaterials. 2023;13:1619.

87. Rahman MA, Yadab MK, Ali MM. Therapeutic advances of curcumin and nanocurcumin in glioblastoma: molecular targets, bioavailability, and drug delivery. Nutrients. 2026;18:194.

88. Shen X, Wang Y, Lin Y, et al. Traditional Chinese medicine-derived active ingredient and formulation therapy for glioma: multi-target mechanisms, drug delivery systems, and advances in clinical translational research. Pharmaceuticals. 2026;19:782.

89. Behl T, Sharma A, Sharma L, et al. Current perspective on the natural compounds and drug delivery techniques in glioblastoma multiforme. Cancers. 2021;13:2765.

90. Rahman MA, Yadab MK, Apu EH, Ali MM. Nanoparticle-based delivery of proteasome inhibitors for glioblastoma therapy: strategies to overcome blood-brain barrier and therapeutic resistance. Biochem Pharmacol. 2026;251:118058.

91. Elati AH, Davies EW, Mishra MV, Winkles JA, Woodworth GF, Kim AJ. Platinum-based therapeutics as emerging multi-modal radiosensitizers in glioblastoma treatment. Adv Drug Deliv Rev. 2026;232:115811.

92. Smiley SB, Zarrinmayeh H, Das SK, Pollok KE, Vannier MW, Veronesi MC. Novel therapeutics and drug-delivery approaches in the modulation of glioblastoma stem cell resistance. Ther Deliv. 2022;13:249-73.

93. Sareen H, Garrett C, Lynch D, et al. The role of liquid biopsies in detecting molecular tumor biomarkers in brain cancer patients. Cancers. 2020;12:1831.

94. Jensen KV, Cseh O, Aman A, Weiss S, Luchman HA. The JAK2/STAT3 inhibitor pacritinib effectively inhibits patient-derived GBM brain tumor initiating cells in vitro and when used in combination with temozolomide increases survival in an orthotopic xenograft model. PLoS One. 2017;12:e0189670.

95. Feng Y, Xu Q, Fang M, Hu C. Anlotinib combined with temozolomide for the treatment of patients with diffuse midline glioma: a case report and literature review. Transl Cancer Res. 2022;11:3876-82.

96. Iorio AL, da Ros M, Genitori L, et al. Tumor response of temozolomide in combination with morphine in a xenograft model of human glioblastoma. Oncotarget. 2017;8:89595-606.

97. Yazici E, Gezen A, Kalay M, et al. Donafenib suppresses glioblastoma progression: potential enhancement of therapeutic response in TMZ-resistant models. Naunyn Schmiedebergs Arch Pharmacol. 2026;399:20505-20.

98. Palizkaran Yazdi M, Barjasteh A, Moghbeli M. MicroRNAs as the pivotal regulators of temozolomide resistance in glioblastoma. Mol Brain. 2024;17:42.

99. Ramar V, Guo S, Hudson B, Liu M. Progress in glioma stem cell research. Cancers. 2023;16:102.

100. Liu X, Liu Y, Li W, et al. The toxic effect and mechanism of TMZ combined with siHOXB9 on glioblastoma cells. Int J Mol Sci. 2025;27:79.

101. Sharma Y, Parihar A, Arya N, et al. Ferroptosis-based nanotherapeutic strategies to overcome temozolomide resistance in glioblastoma: a systematic review and meta-analysis. Curr Oncol. 2026;33:194.

102. Lee CY. Strategies of temozolomide in future glioblastoma treatment. Onco Targets Ther. 2017;10:265-70.